Apixaban News and Research

RSS

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

A recent systematic review and meta-analysis evaluated the safety and efficacy of intensified anticoagulation therapy in COVID-19 patients.

11 Mar 2022

World-renowned expert to lead pediatric cardiology division at Washington University School of Medicine

Andrew C. Glatz, MD, an internationally recognized expert in pediatric interventional cardiology, has been selected to lead the Division of Pediatric Cardiology in the Department of Pediatrics at Washington University School of Medicine in St. Louis.

30 Oct 2021

Study elucidates the use of anticoagulants to treat bleeding in patients with gastrointestinal cancers

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.

5 Jun 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

The COVID-19 pandemic heavily influenced spending on prescription drugs in the U.S. in 2020, according to the ASHP's (American Society of Health-System Pharmacists) National Trends in Prescription Drug Expenditures and Projections for 2021.

21 Apr 2021

Study shows adverse outcomes associated with use of more blood thinners

More blood thinners aren't automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.

19 Apr 2021

UIC conducts three clinical trials to study blood clot prevention in COVID-19 patients

The University of Illinois Chicago will conduct three clinical trials for studying blood clot prevention in patients with COVID-19.

18 Nov 2020

International trial of blood thinners for COVID-19 treatment begins

These trials, known as ACTIV-4 Antithrombotics, are part of the three planned adaptive trials in this area of clinical research, included in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative. They are expected to yield new data on the safety and efficacy of these drugs in the treatment of active and convalescent COVID-19 treatment.

13 Sep 2020

D-dimer - A sensitive novel biomarker of COVID-19 mortality

Now, a new study published on the preprint server medRxiv* reports the use of D-dimer in predicting the risk of mortality in COVID-19.

7 Sep 2020

Blood thinners help reduce the risk of COVID-19 deaths, study finds

Now, a new study by a team of researchers at the Mount Sinai Health System in New York has shown that blood thinners may reduce the risk of death by up to 50 percent among severely ill hospitalized COVID-19 patients.

27 Aug 2020

Anticoagulation therapy associated with improved survival among COVID-19 patients

Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients

27 Aug 2020

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Secondary analysis reinforces safety of blood thinner

Treatment with the blood thinner apixaban was associated with a lower risk of bleeding, death and hospitalization compared with warfarin, regardless of history of prior stroke or blood clot, according to a secondary analysis presented as late breaking science today at the American Stroke Association's International Stroke Conference 2020.

23 Feb 2020

First reported occurrence and treatment of venous thrombosis during spaceflight

Serena Auñón-Chancellor, M.D., M.P.H., Clinical Associate Professor of Medicine at LSU Health New Orleans School of Medicine's branch campus in Baton Rouge, is the lead author of a paper describing a previously unrecognized risk of spaceflight discovered during a study of astronauts involved in long-duration missions.

2 Jan 2020

Clinical benefit of anticoagulants for atrial fibrillation decreases with age, shows study

The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

11 Nov 2019

Study aims to learn more about silent infarction, cognitive decline linked to silent stroke

Can you have a stroke and not know it? Unfortunately, yes. It is a phenomenon called a silent stroke or, more formally, a silent cerebral infarction. Investigators at the University of Alabama at Birmingham and Stanford University want to learn more about silent strokes and their role in brain health, including dementia.

24 Oct 2019

Drug that reverses blood thinning effects stops acute life-threatening bleeding

A drug that reverses the blood thinning effects of factor Xa inhibitors effectively stopped acute life-threatening bleeding in patients taking a factor Xa inhibitor blood thinner drug, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

8 Feb 2019

Proton pump inhibitors in combination with oral anticoagulants reduce GI bleeding risk

A Vanderbilt University Medical Centerstudy published today in JAMA shows that patients already at higher risk for gastrointestinal bleeding gain a marked protection from this risk when they take a proton pump inhibitor in combination with an oral anticoagulant.

4 Dec 2018

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.

4 Dec 2018

Anticoagulant use in East Asian patients with nonvalvular atrial fibrillation

In the current issue of Cardiovascular Innovations and Applications (Volume3,Number 2, 2018, pp. 215-226(12); DOI: https://doi.org/10.15212/CVIA.2017.0033 Chang-Sheng Ma from the Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China considers the use of direct oral anticoagulants for prevention of stroke and systemic embolic events in East Asian patients with nonvalvular atrial fibrillation.

11 Sep 2018

Direct oral anticoagulants associated with reduced risks of major bleeding

New drugs known as direct oral anticoagulants used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

5 Jul 2018